Juniper Pharmaceuticals Inc logo

JNP - Juniper Pharmaceuticals Inc News Story

$11.5 0.0  0.0%

Last Trade - 13/08/18

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £39.3m
Position in Universe th / 6853

Catalent to buy Juniper Pharmaceuticals for $11.50 per share

Tue 3rd July, 2018 9:51am
July 3 (Reuters) - U.S. drug contract manufacturer Catalent
Inc  CTLT.N  said on Tuesday it will buy Juniper Pharmaceuticals
Inc  JNP.O  for $11.50 per share in cash.
    The offer price represents a premium of about 32 percent to
Juniper Pharmaceuticals' closing price of $8.70 on Monday and
values the company at about $127.7 million, according to Thomson
Reuters calculations.
    Catalent has a market value of about $5.58 billion,
according to Thomson Reuters data.
    Juniper Pharmaceuticals shares are up more than 22 percent
since January, when the company said it was exploring strategic
alternatives.
    The deal includes Juniper Pharmaceuticals' U.K. business,
Juniper Pharma Services, and is expected to close in the first
quarter of 2019, Catalent said in a statement.  urn:newsml:reuters.com:*:nBw4mjnV7a
    Catalent said it would continue to support Juniper's Crinone
franchise, a progesterone gel which is its single largest
revenue source and marketed by Merck KGaA  MRCG.DE  outside of
the United States. 
    Juniper Pharmaceuticals separately said its board had
unanimously approved the deal which represents a total equity
value of about $139.6 million on a fully-diluted basis.
 urn:newsml:reuters.com:*:nPn1GyThfa

 (Reporting by Philip  George in Bengaluru; Editing by Sunil
Nair)
 ((P.George@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6749 1609; Reuters Messaging:
p.george@thomsonreuters.net))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.